Selective targeting of certain protein-protein interactions (PPI) in apoptosis pathways has been pursued as a new therapeutic approach to the treatment of cancers and other diseases that stem from the dysregulation of the apoptosis process. Ascentage, a global clinical-stage biotechnology company, is at the forefront of the discovery and development of small molecule therapeutics targeting PPIs in apoptosis pathways. We are the only company targeting all 3 intrinsic apoptotic pathways: Bcl-2, IAP, MDM2-p53. Specifically, our pipeline includes 3 clinical compounds targeting the Bcl-2 family of proteins: APG-1252 for SCLC/NSCLC, lymphoma and other solid tumors; APG-2575 for leukemia, WM and other blood cancers; and AT-101 for CLL. 2 other apoptosis-targeting candidates include APG-1387 (a pan-IAP inhibitor) for Hepatitis B and solid tumors; APG-115 (a MDM2-p53 inhibitor) for AML and solid tumors.